Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24494650 | 1.00 | MAPT (0.54) | MAPTHCAR3NPC1LMNARAB9A | |
| SCHEMBL6737339 | 0.91 | RAB9A (0.45) | MAPTHCAR3NPC1LMNARAB9A | |
| SCHEMBL3434113 | 0.82 | MAPT (0.73) | MAPTHCAR3NPC1LMNARAB9A | |
| SCHEMBL28753181 | 0.80 | RAB9A (0.41) | MAPTNPC1RAB9ASIRT2SIRT1 | |
| SCHEMBL29627173 | 0.80 | RAB9A (0.41) | MAPTNPC1RAB9ASIRT2SIRT1 | |
| SCHEMBL31377132 | 0.80 | LMNA (0.44) | MAPTHCAR3NPC1LMNARAB9A | |
| SCHEMBL31666996 | 0.80 | POLB (0.41) | MAPTHCAR3NPC1LMNARAB9A | |
| SCHEMBL6733449 | 0.76 | HCAR3 (0.39) | MAPTHCAR3NPC1NAMPT | |
| SCHEMBL29974610 | 0.76 | HCAR3 (0.51) | HCAR3NPC1LMNA | |
| SCHEMBL23193770 | 0.76 | HCAR3 (0.51) | HCAR3NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |